| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10159759 | RADIOMEDIX | Pet tracer for imaging of neuroendocrine tumors |
Aug, 2032
(8 years from now) | |
| US10383961 | RADIOMEDIX | PET tracer for imaging of neuroendocrine tumors |
Aug, 2032
(8 years from now) | |
| US11160888 | RADIOMEDIX | PET tracer for imaging of neuroendocrine tumors |
Aug, 2032
(8 years from now) | |
Detectnet is owned by Radiomedix.
Detectnet contains Copper Cu-64 Dotatate.
Detectnet has a total of 3 drug patents out of which 0 drug patents have expired.
Detectnet was authorised for market use on 03 September, 2020.
Detectnet is available in solution;intravenous dosage forms.
Detectnet can be used as use of cu-64 dotatate with positron emission tomography (pet) for localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult patients.
Drug patent challenges can be filed against Detectnet from 03 September, 2024.
The generics of Detectnet are possible to be released after 23 August, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 03, 2025 |
| Orphan Drug Exclusivity(ODE-317) | Sep 03, 2027 |
Drugs and Companies using COPPER CU-64 DOTATATE ingredient
NCE-1 date: 03 September, 2024
Market Authorisation Date: 03 September, 2020
Treatment: Use of cu-64 dotatate with positron emission tomography (pet) for localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult patients
Dosage: SOLUTION;INTRAVENOUS
DETECTNET family patents
